At the news
? BEARISHIMPACT 6/10 8-K filed Sep 11, 2026 at 07:00 ET
Exelixis disclosed that the FDA extended the review period for its NDA for zanzalintinib (in combination with atezolizumab) for metastatic colorectal cancer by three months, moving the PDUFA date to March 3, 2027. The extension was triggered by the company's submission of updated safety and efficacy data in response to an FDA information request, which the FDA deemed a major amendment. This is a material delay for a key pipeline asset, introducing uncertainty around the approval timeline and increasing the risk of a Complete Response Letter.
- FDA extended the review period for Exelixis' NDA for zanzalintinib + atezolizumab in metastatic colorectal cancer by three months.
- The extension was triggered by Exelixis submitting updated safety and efficacy data, which the FDA deemed a major amendment.
- The updated PDUFA action date is March 3, 2027 (previously December 2026).
- The filing contains no financial data, revenue figures, or guidance.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access